MEDISTIM ASA (Oslo , 8th ofJune 2021 )Medistim ASA (OSE: MEDI) is a niche market leader within ultrasound technology with headquarters inOslo, Norway .Medistim develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery. Today,Medistim announces the launch of the Pay Per Procedure (PPP) functionality to our latest MiraQTM platform in the US market.Medistim utilizes several business models to effectively reach different segments of the US market. In addition to traditional capital investments and purchase of consumables, hospitals can choose to enter leasing agreements or Pay Per Procedure (PPP). The PPP functionality has proven to be a popular option with our previous generation of medical device (VeriQTM and VeriQCTM and will now also be available to our MiraQ customers. "Some of our largest customers in theUSA are greatly appreciating the PPP model with their current VeriQTM platform andMedistim wants to make their transition to the latest platform MiraQTM as smooth as possible," saysMedistim President and CEO,Kari E. Krogstad . "The US market is key toMedistim's success, making up about 1/3 of the global potential market, and it is our priority to respond to our customers' preferences." AboutMedistim :Medistim was established in 1984 and has a track record of profitable growth over the past 20 years. The company is a pioneer within its segment and continues to invest in new product development.Medistim has wholly owned subsidiaries with sales organizations in theUSA ,Germany ,UK ,Spain ,Denmark , andNorway , in addition to the about 50 distributors inEurope ,Asia ,Middle East ,Africa ,Canada andSouth America . For more information, visit theMedistim home page: www.medistim.com For more information, contact: President and CEO,Kari E. Krogstad ,Medistim ASA Tel: + 47 918 38 110 Email: kari.krogstad@medistim.com CFO,Thomas Jakobsen ,Medistim ASA Tel: + 47 906 59 940 Email: thomas.jakobsen@medistim.com
Click here for more information
© Oslo Bors ASA, source
